|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-5-15
|
|
pubmed:abstractText |
Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab). The potential benefit of anti-Her-2 therapy is currently investigated in several other HER-2-amplified cancers including gastric cancer. Although HER-2 amplification occurs in more than 10% of gastric cancers, potential heterogeneity of HER-2 amplification and overexpression could represent a major drawback for anti-Her-2 therapy. To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization. HER-2 amplification was seen in 27 (16%) of 166 gastric adenocarcinomas. Amplification was typically high level with more than 20 HER-2 copies per tumor cell and a HER-2/centromere 17 ratio >3. Amplification was associated with intestinal tumor phenotype but unrelated to survival, grading, pT, pN, or pM. Identical HER-2 status was found in primary tumor and their matched lymph node metastases. Moreover, HER-2 and Topoisomerase IIalpha coamplification analysis of 3 to 16 large sections from 8 Her-2-positive gastric cancers did not reveal any heterogeneity of the amplicon site. The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II,
http://linkedlifedata.com/resource/pubmed/chemical/DNA topoisomerase II alpha,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/ERBB2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1532-8392
|
|
pubmed:author |
pubmed-author:BokemeyerCarstenC,
pubmed-author:BrümmendorfTim HTH,
pubmed-author:DancauAna-MariaAM,
pubmed-author:IzbickiJakob RJR,
pubmed-author:KaifiJussuf TJT,
pubmed-author:MarxAndreas HAH,
pubmed-author:MirlacherMartinaM,
pubmed-author:MuthJohannaJ,
pubmed-author:SauterGuidoG,
pubmed-author:SimonRonaldR,
pubmed-author:TharunLarsL,
pubmed-author:YekebasEmreE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
769-77
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19269014-Adenocarcinoma,
pubmed-meshheading:19269014-Adult,
pubmed-meshheading:19269014-Aged,
pubmed-meshheading:19269014-Aged, 80 and over,
pubmed-meshheading:19269014-Antibodies, Monoclonal,
pubmed-meshheading:19269014-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19269014-Antigens, Neoplasm,
pubmed-meshheading:19269014-DNA Topoisomerases, Type II,
pubmed-meshheading:19269014-DNA-Binding Proteins,
pubmed-meshheading:19269014-Female,
pubmed-meshheading:19269014-Gene Amplification,
pubmed-meshheading:19269014-Genes, erbB-2,
pubmed-meshheading:19269014-Humans,
pubmed-meshheading:19269014-In Situ Hybridization, Fluorescence,
pubmed-meshheading:19269014-Lymphatic Metastasis,
pubmed-meshheading:19269014-Male,
pubmed-meshheading:19269014-Middle Aged,
pubmed-meshheading:19269014-Receptor, erbB-2,
pubmed-meshheading:19269014-Stomach Neoplasms,
pubmed-meshheading:19269014-Tissue Array Analysis
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
HER-2 amplification is highly homogenous in gastric cancer.
|
|
pubmed:affiliation |
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Germany. a.marx@uke.de
|
|
pubmed:publicationType |
Journal Article
|
